Understanding oral BPC-157 dosing in preclinical settings requires a careful reading of the source literature — and an immediate acknowledgement of its limits. The oral BPC-157 dosing data reviewed here derive entirely from rodent gavage and drinking-water studies; no validated allometric scaling exists to translate these figures into human-equivalent doses, and any such extrapolation would be scientifically unsupported. With that critical caveat stated, a structured review of what peer-reviewed animal studies actually use — in terms of µg/kg ranges, administration vehicles, dosing frequency, and endpoint timing — provides a useful reference framework for researchers designing their own in-vitro or in-vivo preclinical investigations. For compound sourcing considerations, see our BPC-157 research capsule listing and the accompanying guide to reading peptide CoAs.

Background: Why Oral BPC-157 Dosing Attracts Preclinical Attention

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) first isolated from the gastric juice fraction of Bos taurus. Its molecular weight of approximately 1,419 Da places it at the upper boundary of peptides sometimes observed to survive gastrointestinal transit in measurable quantities when formulated appropriately. Early work by Sikiric and colleagues at the University of Zagreb established a foundational dataset suggesting dose-dependent cytoprotective, angiogenic, and tissue-repair effects following both parenteral and enteral delivery in rat models of gastrointestinal ulceration, tendon transection, muscle crush injury, and ligament rupture.

The oral route is of particular scientific interest because it removes the logistical and sterility requirements of injection-based delivery and, theoretically, allows for mucosal-level as well as systemic pharmacological action. However, the oral bioavailability question remains incompletely resolved in the peer-reviewed literature. Researchers designing gavage studies must therefore treat bioavailability as a confounding variable rather than an established constant. A detailed review of oral bioavailability data across species can be found in our oral BPC-157 bioavailability in preclinical models article.

From a methodological standpoint, the oral route in rodents has been operationalized in three distinct ways across the published literature: (1) intragastric gavage with BPC-157 dissolved in sterile saline, (2) ad libitum access to BPC-157 dissolved in the drinking water at a known concentration, and (3) — more recently and most relevant to capsule-format research — oral gavage of encapsulated or suspension-packed peptide. Each approach carries distinct pharmacokinetic implications that must be weighed when selecting a dosing strategy for a new preclinical protocol.

Oral Dosing Ranges Reported in Rat Models: A Structured Review

The table below synthesizes dose ranges reported across key peer-reviewed rat model studies. All values are reported as published; researchers should consult original sources for full methodological detail, including strain, sex, age, body weight, and concurrent interventions. Note that “effective” in this context means the dose at which statistically significant differences from vehicle control were observed on the primary endpoint specified — it does not imply therapeutic relevance to any species other than the study subject.

A consistent observation across this body of literature is that the 10 µg/kg dose is the most frequently replicated “effective” dose in both gavage and drinking-water paradigms. Doses above 1 mg/kg do not consistently show proportionally greater effect magnitudes, and several studies report a non-monotonic dose-response relationship where mid-range doses (10–100 µg/kg) outperform both lower and higher extremes on histological endpoints. This pattern has been noted in ulcer scoring, macroscopic lesion area quantification, and biomechanical tensile-strength testing of healing tendons.

For context on how these doses relate to tendon-specific outcomes, see our review of oral BPC-157 and tendon repair in rat studies, and for musculoskeletal repair data specifically, our oral BPC-157 muscle repair preclinical protocols page provides further methodological detail.

Oral Administration Methods: Gavage vs. Drinking Water vs. Encapsulation

Three primary oral delivery methods appear in the peer-reviewed preclinical record, each with distinct advantages and methodological trade-offs that researchers must evaluate against their specific experimental objectives.

Intragastric Gavage

Gavage (intragastric intubation) is the most controlled and reproducible oral delivery method in rodents. A fixed volume — typically 1 mL per 100 g body weight in rats — containing a precisely measured BPC-157 concentration in sterile 0.9% saline is delivered directly to the stomach via a blunt-tip feeding needle. This method eliminates inter-animal variability in consumption and ensures that dose-per-animal is tightly controlled. The major disadvantages are procedural stress (which itself can influence gastrointestinal physiology, a particularly meaningful confound in GI-injury models), and the requirement for daily handling. Most gavage studies administer doses between 10:00 and 11:00 AM following a 2-hour fast to standardize gastric emptying state at time of administration.

Drinking Water Administration

Ad libitum drinking-water delivery dissolves BPC-157 at a concentration calculated to deliver approximately 10 µg/kg/day based on published mean daily water intake for the strain and body weight range under study. The key advantage is elimination of handling stress and the ability to maintain continuous low-level exposure over extended durations. The key disadvantage is that actual peptide delivery is estimated rather than measured per animal, and peptide stability in water at room temperature over 24-hour periods must be verified — BPC-157 is generally considered stable in distilled or purified water at room temperature for 24 hours when stored away from direct light, though this has not been systematically characterized under all laboratory conditions. Water bottles should be changed every 24 hours in studies using this method.

Capsule and Encapsulation Formats

A more recent methodological development involves the use of hydroxypropyl methylcellulose (HPMC) capsules or gelatin capsules filled with BPC-157 in a microcrystalline cellulose (MCC) base, administered by gavage or in some cases spontaneous ingestion (after fasting) in larger rodents. This format is most directly analogous to human oral research paradigms and is the format most relevant to researchers studying compound stability, disintegration time, and API release kinetics in the GI environment. Independent laboratory verification of encapsulated peptide stability is an important quality control step; accredited analytical chemistry facilities can confirm peptide identity and concentration in encapsulated formats by HPLC or LC-MS/MS prior to study initiation. Researchers sourcing encapsulated research compounds should always request verified CoA documentation — see our CoA database for reference standards.

Oral Dosing Frequency and Duration in Key Studies

Across the preclinical BPC-157 literature, once-daily (QD) administration is the dominant dosing schedule, used in the majority of published rat and mouse studies. Every-other-day (QOD) schedules have been used in a minority of longer-duration studies (typically those extending beyond 28 days) to reduce cumulative handling burden without substantially altering the time-averaged exposure profile given the peptide’s apparent rapid renal clearance and the current absence of evidence for tissue accumulation with repeat dosing.

Duration of dosing varies meaningfully by model type:

• Acute GI injury models (single-dose or 3–5 day models): Single prophylactic gavage at a fixed time before injury induction, or once-daily treatment for 3–7 days post-injury.
• Chronic ulcer / inflammatory models: 7–21 days of once-daily gavage, with endpoint assessment at 24 hours post-final dose in most protocols.
• Musculoskeletal repair models: 14–42 days of once-daily gavage or continuous drinking-water exposure, with biomechanical and histological endpoints assessed at day 14, 21, or 42.
• Neuroprotection / spinal cord injury models: Typically 14–28 days of once-daily gavage starting immediately post-injury, with functional (motor scoring), histological, and immunohistochemical endpoints.